Containment Immune Response Medicine Packaging 
Pharmaceutical Technology
JULY 29, 2022
Pfizer completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted bivalent Covid-19 vaccine candidate, based on the BA.1 And we are very prepared and have data that will answer those questions, what would be the advantage of shifting to an Omicron-containing vaccine, whether it's monovalent or bivalent.”
Drug Discovery World
SEPTEMBER 29, 2022
Over two decades ago, the National Academy of Medicine declared the development of a vaccine to prevent congenital CMV infection one of the highest public health priorities 11. Human CMV contains a large viral genome enclosed in a capsid, which is surrounded by an outer envelope that contains at least 19 proteins 17,18.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
DECEMBER 17, 2020
NASDAQ: REGN ) today announced that the New England Journal of Medicine (NEJM) has published initial clinical data from an ongoing seamless Phase 1/2/3 trial of the antibody cocktail casirivimab and imdevimab in non-hospitalized patients with COVID-19. TARRYTOWN, N.Y. , 17, 2020 /PRNewswire/ — Regeneron Pharmaceuticals, Inc.
Drug Discovery World
DECEMBER 15, 2022
While viral vectors can be highly active, they can lead to only transient expression (rAAV, AdV), can lead to adverse immune responses (AdV) or can integrate randomly into the genome (LV). Each comes with its own drawbacks, including immunogenicity, size restrictions, and off-target effects 6. References.
The Pharma Data
NOVEMBER 20, 2020
The clinical evidence from Regeneron’s outpatient trial suggests that monoclonal antibodies such as casirivimab and imdevimab have the greatest benefit when given early after diagnosis and in patients who have not yet mounted their own immune response or who have high viral load.
The Pharma Data
OCTOBER 28, 2020
“We continue to see the strongest effects in patients who are most at risk for poor outcomes due to high viral load, ineffective antibody immune response at baseline, or pre-existing risk factors. Yancopoulos , M.D., President and Chief Scientific Officer of Regeneron. Regeneron has shared these results with the U.S.
The Pharma Data
DECEMBER 29, 2020
The analysis was prospectively designed to focus on patients who had not yet mounted their own immune response to SARS-CoV-2 (i.e., About Regeneron Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. futility analysis). .
Expert insights. Personalized for you.
130 
Let's personalize your content